AcelRx Pharmaceuticals Inc (ACRX)

3.05
0.15 5.17
NASDAQ : Health Care
Prev Close 2.90
Open 2.95
Day Low/High 2.85 / 3.10
52 Wk Low/High 2.40 / 5.88
Volume 383.69K
Avg Volume 295.10K
Exchange NASDAQ
Shares Outstanding 45.33M
Market Cap 131.47M
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

AcelRx Pharmaceuticals To Host Analyst & Investor Event On December 1, 2016

AcelRx Pharmaceuticals To Host Analyst & Investor Event On December 1, 2016

- Expert panel to discuss market opportunity in emergency medicine for investigational agent ARX-04 (sufentanil sublingual tablet, 30 mcg) for the treatment of moderate-to-severe acute pain

ACRX: Insiders vs. Shorts

ACRX: Insiders vs. Shorts

The most recent short interest data was recently released for the 09/30/2016 settlement date, and AcelRx Pharmaceuticals Inc is one of the most shorted stocks of the Russell 3000, based on 8.72 "days to cover" versus the median component at 5.36. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Here's Why AcelRx Pharmaceuticals (ACRX) Stock Gained Today

Here's Why AcelRx Pharmaceuticals (ACRX) Stock Gained Today

AcelRx Pharmaceuticals (ACRX) announced on Thursday that ARX-04, its experimental pain relief drug, had positive results in a phase III clinical trial.

AcelRx Pharmaceuticals To Announce Topline Results In Phase 3 Study Of ARX-04 In Patients With Post-Operative Moderate-to-Severe Acute Pain

AcelRx Pharmaceuticals To Announce Topline Results In Phase 3 Study Of ARX-04 In Patients With Post-Operative Moderate-to-Severe Acute Pain

Management to host conference call tomorrow at 9:00 a.m. ET (6:00 a.m. PT) Thursday, September 15th

AcelRx Pharmaceuticals' ARX-04 Phase 3 Trial Met Its Primary Endpoint, Reduced Pain Intensity In ER Patients With Moderate-to-Severe Acute Pain

AcelRx Pharmaceuticals' ARX-04 Phase 3 Trial Met Its Primary Endpoint, Reduced Pain Intensity In ER Patients With Moderate-to-Severe Acute Pain

- Topline SAP302 Results Presented at Military Health System Research Symposium -

AcelRx Publishes A Review Of Hospital-Based Opioid Patient-Controlled Analgesia, Risks And Pharmacoeconomics

AcelRx Publishes A Review Of Hospital-Based Opioid Patient-Controlled Analgesia, Risks And Pharmacoeconomics

- Zalviso Clinical Program Highlighted in Publication in Hospital Pharmacy -

First Week of ACRX September 16th Options Trading

First Week of ACRX September 16th Options Trading

Investors in AcelRx Pharmaceuticals Inc saw new options begin trading this week, for the September 16th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 233 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

AcelRx Pharmaceuticals Announces Presentation Of Phase 3 Sufentanil Sublingual 30 Mcg Tablet (ARX-04) Data At The European Congress Of Ambulatory Surgery

AcelRx Pharmaceuticals Announces Presentation Of Phase 3 Sufentanil Sublingual 30 Mcg Tablet (ARX-04) Data At The European Congress Of Ambulatory Surgery

Phase 3 Clinical Data Highlights Safety and Efficacy of Sublingual Sufentanil in Outpatient Abdominal Surgery Populations